tbuckley/cabot-search huggingface dataset:
Out of the Park
Authors: Rebecca A. Snyder
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TCT CONNECT-82 Prognostic Value of Serial Neutrophil-to-Lymphocyte Ratio in Patients Undergoing Transcatheter or Surgical Aortic Valve Replacement: The PARTNER I-II Trials and Registries
Authors: Bahira Shahim, Bjorn Redfors, Shmuel Chen, Torsten Dahlen, Brian Lindman, Samir Kapadia, Zachary Gertz, Aaron Crowley, Ditian Li, Maria Alu, Vinod Thourani, Susheel Kodali, Alan Zajarias, Vasilis Babaliaros, Robert Guyton, Sammy Elmariah, Howard Herrmann, Michael Mack, Martin Leon, Isaac George
Journal: Journal of the American College of Cardiology (2020)
Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients
Authors: Ulrike Leiter, Carmen Loquai, Lydia Reinhardt, David Rafei-Shamsabadi, Ralf Gutzmer, Katharina Kaehler, Lucie Heinzerling, Jessica C Hassel, Valerie Glutsch, Judith Sirokay, Nora Schlecht, Albert Rübben, Thilo Gambichler, Kerstin Schatton, Claudia Pfoehler, Cindy Franklin, Patrick Terheyden, Sebastian Haferkamp, Peter Mohr, Lena Bischof, Elisabeth Livingstone, Lisa Zimmer, Michael Weichenthal, Dirk Schadendorf, Andreas Meiwes, Ulrike Keim, Claus Garbe, Jürgen Christian Becker, Selma Ugurel
Journal: Journal for ImmunoTherapy of Cancer (2020)

Skin cancers are known for their strong immunogenicity, which may contribute to a high treatment efficacy of immune checkpoint inhibition (ICI). However, a considerable proportion of patients with skin cancer is immuno-compromised by concomitant diseases. Due to their previous exclusion from clinical trials, the ICI treatment efficacy is poorly investigated in these patients. The present study analyzed the ICI treatment outcome in advanced patients with skin cancer with a concomitant hematological malignancy.This retrospective multicenter study included patients who were treated with ICI for locally advanced or metastatic melanoma (MM), cutaneous squamous cell carcinoma (cSCC), or Merkel cell carcinoma (MCC), and had a previous diagnosis of a hematological malignancy irrespective of disease activity or need of therapy at ICI treatment start. Comparator patient cohorts without concomitant hematological malignancy were extracted from the prospective multicenter skin cancer registry ADOREG. Treatment outcome was measured as best overall response, progression-free (PFS), and overall survival (OS).84 patients (MM, n=52; cSCC, n=15; MCC, n=17) with concomitant hematological malignancy were identified at 20 skin cancer centers. The most frequent concomitant hematological malignancies were non-Hodgkin's lymphoma (n=70), with chronic lymphocytic leukemia (n=32) being the largest entity. While 9 patients received ICI in an adjuvant setting, 75 patients were treated for advanced non-resectable disease (55 anti-PD-1; 8 anti-PD-L1; 5 anti-CTLA-4; 7 combinations). In the latter 75 patients, best objective response (complete response+partial response) was 28.0%, disease stabilization was 25.3%, and 38.6% showed progressive disease (PD). Subdivided by skin cancer entity, best objective response was 31.1% (MM), 26.7% (cSCC), and 18.8% (MCC). Median PFS was 8.4 months (MM), 4.0 months (cSCC), and 5.7 months (MCC). 1-year OS rates were 78.4% (MM), 65.8% (cSCC), and 47.4% (MCC). Comparison with respective ADOREG patient cohorts without hematological malignancy (n=392) revealed no relevant differences in ICI therapy outcome for MM and MCC, but a significantly reduced PFS for cSCC (p=0.002).ICI therapy showed efficacy in advanced patients with skin cancer with a concomitant hematological malignancy. Compared with patients without hematological malignancy, the observed ICI therapy outcome was impaired in cSCC, but not in MM or MCC patients.
TCT CONNECT-137 Autoimmune Connective Tissue Diseases and Aortic Valve Replacement Outcomes: A Population-Based Study
Authors: Mohamed Gad, Devora Lichtman, Anas Saad, Mouin Abdallah, Samir Kapadia, Venu Menon, Heba Wassif
Journal: Journal of the American College of Cardiology (2020)
SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020
Authors: Sheila F Lumley, David W Eyre, Anna L McNaughton, Alison Howarth, Sarah Hoosdally, Stephanie B Hatch, James Kavanagh, Kevin K Chau, Louise O Downs, Stuart Cox, Laura Dunn, Anita Justice, Susan Wareing, Kate Dingle, Justine Rudkin, Kathryn Auckland, Alexander Fyfe, Jai Bolton, Robert Paton, Alexander J Mentzer, Katie Jeffery, Monique I Andersson, Tim James, Tim E A Peto, Brian D Marsden, Gavin Screaton, Richard J Cornall, Paul Klenerman, Daniel Ebner, David I Stuart, Derrick W Crook, Nicole Stoesser, Stephen H Kennedy, Craig Thompson, Sunetra Gupta, Philippa C Matthews
Journal: Eurosurveillance (2020)

SARS-CoV-2 IgG screening of 1,000 antenatal serum samples in the Oxford area, United Kingdom, between 14 April and 15 June 2020, yielded a 5.3% seroprevalence, mirroring contemporaneous regional data. Among the 53 positive samples, 39 showed in vitro neutralisation activity, correlating with IgG titre (Pearson’s correlation p&lt;0.0001). While SARS-CoV-2 seroprevalence in pregnancy cohorts could potentially inform population surveillance, clinical correlates of infection and immunity in pregnancy, and antenatal epidemiology evolution over time need further study.
Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma
Authors: Hampartsoum B Barsoumian, Rishab Ramapriyan, Ahmed I Younes, Mauricio S Caetano, Hari Menon, Nathan I Comeaux, Taylor R Cushman, Jonathan E Schoenhals, Alexandra P Cadena, Timothy P Reilly, Dawei Chen, Fatemeh Masrorpour, Ailin Li, David S Hong, Adi Diab, Quynh-Nhu Nguyen, Isabella Glitza, Renata Ferrarotto, Stephen G Chun, Maria Angelica Cortez, James Welsh
Journal: Journal for ImmunoTherapy of Cancer (2020)

Background Despite some successes with checkpoint inhibitors for treating cancer, most patients remain refractory to treatment, possibly due to the inhibitory nature of the tumor stroma that impedes the function and entry of effector cells. We devised a new technique of combining immunotherapy with radiotherapy (XRT), more specifically low-dose XRT, to overcome the stroma and maximize systemic outcomes. Methods We bilaterally established 344SQ lung adenocarcinoma tumors in 129Sv/Ev mice. Primary and secondary tumors were irradiated with either high-dose or low-dose of XRT with systemic anti-programmed cell death protein 1 and anti-cytotoxic T-lymphocyte associated protein 4 administration. Survival and tumor growth were monitored for the various groups, and secondary tumors were phenotyped by flow cytometry for immune populations. Tumor growth factor-beta (TGF-β) cytokine levels were assessed locally after low-dose XRT, and specific immune-cell depletion experiments were conducted to identify the major contributors to the observed systemic antitumor effect. Results Through our preclinical and clinical studies, we observed that when tumor burden was high, there was a necessity of combining high-dose XRT to ‘prime’ T cells at the primary tumor site, with low-dose XRT directed to secondary (metastatic) tumors to ‘modulate the stroma’. Low-dose XRT improved the antitumor outcomes of checkpoint inhibitors by favoring M1 macrophage polarization, enhancing natural killer (NK) cell infiltration, and reducing TGF-β levels. Depletion of CD4 + T cells and NK cells abrogated the observed antitumor effect. Conclusion Our data extend the benefits of low-dose XRT to reprogram the tumor environment and improve the infiltration and function of effector immune cells into secondary tumors.
Microdeletion in Chromosome 17 Cytoband q21.31 Identified As Located within the KANSL1 Gene Prevailed in Flt3-ITD Negative Normal Karyotype AML Patients As Opposed to Their AML Counterparts and Influenced the Phenotype of the Disease
Authors: Emilia Jaskula, Andrzej Lange, Mariola Sedzimirska, Jakub Chrustowicz, Agnieszka Tarnowska, Janusz Lange
Journal: Blood (2017)
TCT CONNECT-152 Comparing the Rate of Side Branch Occlusion Between Jailed Balloon Technique and Jailed Wire Technique During High-Risk Coronary Bifurcation Intervention: Subgroup Analysis of the CIT-RESOLVE Trial
Authors: Dong Zhang, Kefei Dou, Changdong Guan, Hongwei Pan, Bo Xu
Journal: Journal of the American College of Cardiology (2020)
TCT CONNECT-217 Hydroxychloroquine and Azithromycin Usage in African American Patients With Coronavirus Disease 2019 (COVID-19) and Their Effects on QT Interval
Authors: Mohammed Al-Sadawi, Adam Budzikowski, Justin Lee, Ahmed Jallad, Baho Sidiqi, Ishmam Ibtida, Yusra Qaiser, Harshith Priyan Chandrakumar, Ashkan Tadayoni, Paul Madaj
Journal: Journal of the American College of Cardiology (2020)
Training in Surgery—Reply
Authors: Sara P. Myers, Stephanie M. Downs-Canner, Matthew R. Rosengart
Journal: JAMA Surgery (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Anticancer drug-loaded mesenchymal stem cells for targeted cancer therapy
Authors: Yukiya Takayama, Kosuke Kusamori, Chihiro Tsukimori, Yosuke Shimizu, Mika Hayashi, Ikumi Kiyama, Hidemasa Katsumi, Toshiyasu Sakane, Akira Yamamoto, Makiya Nishikawa
Journal: Journal of Controlled Release (2020)
TCT CONNECT-5 Six-Month and One-Year Outcomes for Transcatheter Repair in Patients With Mitral Regurgitation From the CLASP Study
Authors: Robert Smith, Molly Szerlip, Scott Lim, Raj Makkar, Saibal Kar, Robert Kipperman, Konstantinos Spargias, William O'Neill, Martin Ng, Neil Fam, Michael Rinaldi, Owen Raffel, Darren Walters, Justin Levisay, Matteo Montorfano, Azeem Latib, Gideon Cohen, Ulrich Schäfer, Leo Marcoff, John Webb
Journal: Journal of the American College of Cardiology (2020)
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
Authors: George L. Bakris, Rajiv Agarwal, Stefan D. Anker, Bertram Pitt, Luis M. Ruilope, Peter Rossing, Peter Kolkhof, Christina Nowack, Patrick Schloemer, Amer Joseph, Gerasimos Filippatos
Journal: New England Journal of Medicine (2020)

Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials involving patients with chronic kidney disease (CKD) and type 2 diabetes. However, its long-term effects on kidney and cardiovascular outcomes are unknown.In this double-blind trial, we randomly assigned 5734 patients with CKD and type 2 diabetes in a 1:1 ratio to receive finerenone or placebo. Eligible patients had a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of 30 to less than 300, an estimated glomerular filtration rate (eGFR) of 25 to less than 60 ml per minute per 1.73 m2 of body-surface area, and diabetic retinopathy, or they had a urinary albumin-to-creatinine ratio of 300 to 5000 and an eGFR of 25 to less than 75 ml per minute per 1.73 m2. All the patients were treated with renin-angiotensin system blockade that had been adjusted before randomization to the maximum dose on the manufacturer's label that did not cause unacceptable side effects. The primary composite outcome, assessed in a time-to-event analysis, was kidney failure, a sustained decrease of at least 40% in the eGFR from baseline, or death from renal causes. The key secondary composite outcome, also assessed in a time-to-event analysis, was death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure.During a median follow-up of 2.6 years, a primary outcome event occurred in 504 of 2833 patients (17.8%) in the finerenone group and 600 of 2841 patients (21.1%) in the placebo group (hazard ratio, 0.82; 95% confidence interval [CI], 0.73 to 0.93; P = 0.001). A key secondary outcome event occurred in 367 patients (13.0%) and 420 patients (14.8%) in the respective groups (hazard ratio, 0.86; 95% CI, 0.75 to 0.99; P = 0.03). Overall, the frequency of adverse events was similar in the two groups. The incidence of hyperkalemia-related discontinuation of the trial regimen was higher with finerenone than with placebo (2.3% and 0.9%, respectively).In patients with CKD and type 2 diabetes, treatment with finerenone resulted in lower risks of CKD progression and cardiovascular events than placebo. (Funded by Bayer; FIDELIO-DKD ClinicalTrials.gov number, NCT02540993.).
TCT CONNECT-144 Post-Procedural Versus Discharge Echocardiogram Hemodynamics Post-Valve-in-Valve Transcatheter Aortic Valve Replacement: A Multi-Center Trial
Authors: Amer N. Kadri, Sammy Elmariah, Karim Al-Azizi, George Hanzel, Francis Shannon, Srinivasa Potluri, Justin Schaffer, Ahmed Ali, Sara Khodor, Alexander Camacho, Alexandra Selberg, Molly Szerlip, Michael Mack, Amr Abbas
Journal: Journal of the American College of Cardiology (2020)
TCT CONNECT-371 Drug-Coated Balloon Contact Pressure Predicts Endoluminal Coating Distribution
Authors: Abraham Tzafriri, Benny Muraj, Fernando Gacia-Polite, Antonio-Gabino Salazar-Martin, Peter Markham, Anna-Maria Spognardi, Brett Zani, Mazen Albaghdadi, Steve Alston, Elazer Edelman
Journal: Journal of the American College of Cardiology (2020)
TCT CONNECT-435 Improved Safety With Superior Efficacy of Less-Invasive Hybrid Ventricular Reconstruction for Ischemic Heart Failure
Authors: Patrick Klein, Lon Annest, Ralph Stephan von Bardeleben, Sebastian Kelle, Gregg Stone, Andrew Wechsler, Assad Haneya, Thorsten Hanke
Journal: Journal of the American College of Cardiology (2020)
A phylogenetic analysis identifies heterogeneity among hepatocellular carcinomas
Authors: Katherine A. McGlynn, Michael N. Edmonson, Rita A. Michielli, Thomas W. London, Wen Yao Lin, Gong-Chao Chen, Fu-Min Shen, Kenneth H. Buetow
Journal: Hepatology (2002)

Primary hepatocellular carcinoma (HCC) is a significant cause of cancer morbidity and mortality on the global scale. Although epidemiologic studies have identified major risk factors for HCC, the sequence of oncogenic events at the molecular level remains poorly understood. While genetic allele loss appears to be a common event, the significance of the loss is not clear. In order to determine whether allele loss appears to be a random event among HCCs or whether patterns of loss cluster in groups of tumors, a phylogenetic approach was used to examine 32 tumors for genome-wide loss of heterozygosity employing 391 markers. Clusters identified by the phylogenetic analysis were then contrasted to compare candidate locus variation among individuals and to determine whether certain clusters exhibited higher loss rates than other clusters. The analysis found that 3 major and 1 minor cluster of loss could be identified and, further, these clusters were distinguished by variable rates of loss (cluster 1,29%; cluster 3, 16%). The analyses also indicated that the allele loss rates in HCC were not insignificant and that the patterns of allele loss were complex. In addition, the results indicated that an individual’s constitutional genotype at the EPHX1 locus may be a critical factor in determining the path of tumor evolution. In conclusion, it appears that in HCC, allele loss is not random, but clusters into definable groups that are characterized by distinctive rates of loss. (Hepatology2002;36:1341-1348).
TCT CONNECT-208 Accuracy of Quantitative Coronary Angiography and Visual Assessment for Predicting Functionally Significant Stenoses in Women With Chronic Coronary Syndrome
Authors: Mauro Gitto, Roy Taoutel, Marabel Schneider, Nikolaos Papoutsidakis, Scott Ardito, Ecaterina Cristea, Alexandra Lansky, S. Elissa Altin
Journal: Journal of the American College of Cardiology (2020)
Antenatal Dexamethasone for Early Preterm Birth in Low-Resource Countries
Authors: Olufemi T Oladapo, Joshua P Vogel, Gilda Piaggio, My-Huong Nguyen, Fernando Althabe, A Metin Gülmezoglu, Rajiv Bahl, Suman P N Rao, Ayesha De Costa, Shuchita Gupta, Abdullah H Baqui, Rasheda Khanam, Mohammod Shahidullah, Saleha B Chowdhury, Salahuddin Ahmed, Nazma Begum, Arunangshu D Roy, M A Shahed, Iffat A Jaben, Farida Yasmin, M Mozibur Rahman, Anjuman Ara, Soofia Khatoon, Gulshan Ara, Shaheen Akter, Nasreen Akhter, Probhat R Dey, M Abdus Sabur, Mohammad T Azad, Shahana F Choudhury, M A Matin, Shivaprasad S Goudar, Sangappa M Dhaded, Mrityunjay C Metgud, Yeshita V Pujar, Manjunath S Somannavar, Sunil S Vernekar, Veena R Herekar, Shailaja R Bidri, Sangamesh S Mathapati, Preeti G Patil, Mallanagouda M Patil, Muttappa R Gudadinni, Hidaytullah R Bijapure, Ashalata A Mallapur, Geetanjali M Katageri, Sumangala B Chikkamath, Bhuvaneshwari C Yelamali, Ramesh R Pol, Sujata S Misra, Leena Das, Saumya Nanda, Rashmita B Nayak, Bipsa Singh, Zahida Qureshi, Fredrick Were, Alfred Osoti, George Gwako, Ahmed Laving, John Kinuthia, Hafsa Mohamed, Nawal Aliyan, Adelaide Barassa, Elizabeth Kibaru, Margaret Mbuga, Lydia Thuranira, Njoroge J Githua, Bernadine Lusweti, Adejumoke I Ayede, Adegoke G Falade, Olubukola A Adesina, Atinuke M Agunloye, Oluwatosin O Iyiola, Wilfred Sanni, Ifeyinwa K Ejinkeonye, Hadiza A Idris, Chinyere V Okoli, Theresa A Irinyenikan, Omolayo A Olubosede, Olaseinde Bello, Olufemi M Omololu, Olanike A Olutekunbi, Adesina L Akintan, Olorunfemi O Owa, Rosena O Oluwafemi, Ireti P Eniowo, Adetokunbo O Fabamwo, Elizabeth A Disu, Joy O Agbara, Ebunoluwa A Adejuyigbe, Oluwafemi Kuti, Henry C Anyabolu, Ibraheem O Awowole, Akintunde O Fehintola, Bankole P Kuti, Anthony D Isah, Eyinade K Olateju, Olusanya Abiodun, Olabisi F Dedeke, Francis B Akinkunmi, Lawal Oyeneyin, Omotayo Adesiyun, Hadijat O Raji, Adedapo B A Ande, Ikechukwu Okonkwo, Shabina Ariff, Sajid B Soofi, Lumaan Sheikh, Saima Zulfiqar, Sadia Omer, Raheel Sikandar, Salma Sheikh, Daniel Giordano, Hugo Gamerro, Guillermo Carroli, Jose Carvalho, James Neilson, Elizabeth Molyneux, Khalid Yunis, Kidza Mugerwa, Harish K Chellani
Journal: New England Journal of Medicine (2020)

The safety and efficacy of antenatal glucocorticoids in women in low-resource countries who are at risk for preterm birth are uncertain.
CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy
Authors: Semjon Willier, Paula Rothämel, Maximilian Hastreiter, Jonas Wilhelm, Dana Stenger, Franziska Blaeschke, Meino Rohlfs, Theresa Kaeuferle, Irene Schmid, Michael H. Albert, Vera Binder, Marion Subklewe, Christoph Klein, Tobias Feuchtinger
Journal: Blood (2020)
TCT CONNECT-75 Evaluating In-Hospital Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis and Obstructive Sleep Apnea
Authors: Louis Vincent, Jelani Grant, Bertrand Ebner, Jennifer Manning, Neal Olarte, Odunayo Olorunfemi, Eduardo De Marchena, Mauricio Cohen
Journal: Journal of the American College of Cardiology (2020)
TCT CONNECT-299 Long-Term Clinical Outcomes After Revascularization With PCI and CABG for Left Main Disease in Elderly Versus Young Patients: The EXCEL trial
Authors: Christopher Song, Shmuel Chen, Mahesh Madhavan, Erick Schampaert, Patrick Serruys, Nicholas Lembo, William Brown, Pawel Buszman, Andrzej Bochenek, Pierre Page, Ovidiu Dressler, Gregg Stone
Journal: Journal of the American College of Cardiology (2020)
Longevity, clonal relationship, and transcriptional program of celiac disease–specific plasma cells
Authors: Ida Lindeman, Chunyan Zhou, Linn M. Eggesbø, Zhichao Miao, Justyna Polak, Knut E.A. Lundin, Jørgen Jahnsen, Shuo-Wang Qiao, Rasmus Iversen, Ludvig M. Sollid
Journal: The Journal of Experimental Medicine (2020)

Disease-specific plasma cells (PCs) reactive with transglutaminase 2 (TG2) or deamidated gluten peptides (DGPs) are abundant in celiac disease (CeD) gut lesions. Their contribution toward CeD pathogenesis is unclear. We assessed expression of markers associated with PC longevity in 15 untreated and 26 treated CeD patients in addition to 13 non-CeD controls and performed RNA sequencing with clonal inference and transcriptomic analysis of 3,251 single PCs. We observed antigen-dependent V-gene selection and stereotypic antibodies. Generation of recombinant DGP-specific antibodies revealed a key role of a heavy chain residue that displays polymorphism, suggesting that immunoglobulin gene polymorphisms may influence CeD-specific antibody responses. We identified transcriptional differences between CeD-specific and non–disease-specific PCs and between short-lived and long-lived PCs. The short-lived CD19+CD45+ phenotype dominated in untreated and short-term–treated CeD, in particular among disease-specific PCs but also in the general PC population. Thus, the disease lesion of untreated CeD is characterized by massive accumulation of short-lived PCs that are not only directed against disease-specific antigens.
TCT CONNECT-128 Impact of Time-of-Day of Surgical or Transcatheter Aortic Valve Replacement Procedure on Outcomes: A Propensity-score Matched Analysis From PARTNER Trials
Authors: Flavien Vincent, Vinod Thourani, Bjorn Redfors, Julien Ternacle, David Cohen, Rebecca Hahn, Ditian Li, Aaron Crowley, John Webb, Michael Mack, Samir Kapadia, Mark Russo, Martin Leon, Philippe Pibarot
Journal: Journal of the American College of Cardiology (2020)
Is COVID-19 a Perfect Storm for Parkinson’s Disease?
Authors: Patrik Brundin, Avindra Nath, J. David Beckham
Journal: Trends in Neurosciences (2020)

Three recent case reports (by Méndez-Guerrero et al.,Cohen et al., and Faber et al.) describe the development of acute parkinsonism following coronavirus disease 2019 (COVID-19). We discuss possible underlying cellular and molecular mechanisms, and whether COVID-19 might be associated with elevated long-term risk of Parkinson's disease (PD).